MB-105 is under clinical development by March Biosciences and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MB-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MB-105 overview
MB-105 is under development for the treatment of T cell-acute lymphoblastic lymphoma, T-non-Hodgkin lymphoma, T-cell acute lymphoblastic leukemia (T-ALL) including angioimmunoblastic T-cell lymphoma (AITL), enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma, T cell prolymphocytic leukemia with symptomatic disease, extranodal NK/T cell lymphoma, Mycosis fungoides/ sezary syndrome, chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. The therapy comprises of T cells genetically modified by lentiviral transduction to express a chimeric antigen receptor (CAR) targeting the antigen CD5. It is administered by intravenous route as an infusion.
March Biosciences overview
March Biosciences is a cell therapy company that develops CAR-T cell drugs for cancer immunotherapy and to transform patient care in the hematological malignancies. The company is headquartered in Houston, Texas, the US.
For a complete picture of MB-105’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
